Cartesian Therapeutics Inc (RNAC)
34.40
+2.96
(+9.41%)
USD |
NASDAQ |
May 31, 16:00
34.47
+0.07
(+0.20%)
After-Hours: 20:00
Cartesian Therapeutics Cash from Operations (Quarterly): -15.92M for March 31, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -15.92M |
| December 31, 2023 | -23.29M |
| September 30, 2023 | -9.215M |
| June 30, 2023 | -9.895M |
| March 31, 2023 | -8.765M |
| December 31, 2022 | -11.85M |
| September 30, 2022 | 4.353M |
| June 30, 2022 | -12.27M |
| March 31, 2022 | -11.86M |
| December 31, 2021 | -31.46M |
| September 30, 2021 | -10.75M |
| June 30, 2021 | -6.043M |
| March 31, 2021 | -12.13M |
| December 31, 2020 | -7.25M |
| September 30, 2020 | 65.64M |
| June 30, 2020 | -11.81M |
| March 31, 2020 | -11.70M |
| December 31, 2019 | -12.88M |
| September 30, 2019 | -11.12M |
| Date | Value |
|---|---|
| June 30, 2019 | -7.197M |
| March 31, 2019 | -20.24M |
| December 31, 2018 | -12.75M |
| September 30, 2018 | -16.03M |
| June 30, 2018 | -16.97M |
| March 31, 2018 | -13.41M |
| December 31, 2017 | -12.66M |
| September 30, 2017 | -15.44M |
| June 30, 2017 | -8.614M |
| March 31, 2017 | -15.32M |
| December 31, 2016 | 1.482M |
| September 30, 2016 | -5.466M |
| June 30, 2016 | -5.607M |
| March 31, 2016 | -10.17M |
| December 31, 2015 | -7.64M |
| September 30, 2015 | -5.612M |
| June 30, 2015 | -4.313M |
| March 31, 2015 | -4.898M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-31.46M
Minimum
Dec 2021
65.64M
Maximum
Sep 2020
-7.770M
Average
-11.41M
Median
Cash from Operations (Quarterly) Benchmarks
| Marinus Pharmaceuticals Inc | -37.46M |
| Adial Pharmaceuticals Inc | -1.626M |
| Poseida Therapeutics Inc | -15.14M |
| Viracta Therapeutics Inc | -7.849M |
| Biomea Fusion Inc | -32.03M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -0.602M |
| Cash from Financing (Quarterly) | 43.03M |
| Free Cash Flow | -58.99M |
| Free Cash Flow Per Share (Quarterly) | -3.051 |
| Free Cash Flow to Equity (Quarterly) | -16.52M |
| Free Cash Flow Yield | -32.69% |